Success Metrics

Clinical Success Rate
100.0%

Based on 1 completed trials

Completion Rate
100%(1/1)
Active Trials
1(33%)
Results Posted
0%(0 trials)

Phase Distribution

Ph not_applicable
1
33%

Phase Distribution

0

Early Stage

0

Mid Stage

0

Late Stage

Phase Distribution1 total trials
N/ANon-phased studies
1(100.0%)

Highest Phase Reached

Unknown

Trial Status & Enrollment

Completion Rate

100.0%

1 of 1 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

1

trials recruiting

Total Trials

3

all time

Status Distribution
Active(2)
Completed(1)

Detailed Status

Recruiting1
Completed1
Not yet recruiting1

Development Timeline

Analytics

Development Status

Total Trials
3
Active
1
Success Rate
100.0%
Most Advanced
N/A

Trials by Phase

N/A1 (100.0%)

Trials by Status

recruiting133%
completed133%
not_yet_recruiting133%

Recent Activity

1 active trials
Showing 3 of 3
recruiting

CHOICE KERGUELEN 2 : Consequences of Longterm Confinement on Immunity in the Sub-Antarctic Islands : Follow-up of Volunteers on the Kerguelen Islands

NCT07275489
completed

CHOICE KERGUELEN 1: Consequences of Longterm Confinement on Immunity in the Sub-Antarctic Islands: Inclusion of Volunteers Before Departure to the Kerguelen Islands

NCT07065253
not_yet_recruitingnot_applicable

Diagnostic Performance of Plasma Biomarkers of Alzheimer's Disease Compared With CSF Markers

NCT06304129

Clinical Trials (3)

Showing 3 of 3 trials
NCT07275489

CHOICE KERGUELEN 2 : Consequences of Longterm Confinement on Immunity in the Sub-Antarctic Islands : Follow-up of Volunteers on the Kerguelen Islands

Recruiting
NCT07065253

CHOICE KERGUELEN 1: Consequences of Longterm Confinement on Immunity in the Sub-Antarctic Islands: Inclusion of Volunteers Before Departure to the Kerguelen Islands

Completed
NCT06304129Not Applicable

Diagnostic Performance of Plasma Biomarkers of Alzheimer's Disease Compared With CSF Markers

Not Yet Recruiting

All 3 trials loaded

Drug Details

Intervention Type
OTHER
Total Trials
3